Navigation Links
Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year
Date:10/5/2009

LONDON, Oct. 5 /PRNewswire/ -- The 2009 Frost & Sullivan European Medical Imaging Emerging Company of the Year Award in the radiology applications market is conferred on Viatronix for its innovative 3D computer imaging technologies in the diagnostic imaging space.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

"Despite being a young company, Viatronix has shown dedication to both developing and distributing high-end, organ-specific 3D clinical solutions, while advancing its ability to address changing market trends," says Frost & Sullivan Research Analyst Gideon Praveen Kumar. "The company has emerged as a leader in the 3D imaging market in Europe as a result of recent high profile partnerships and its active engagement with the medical community through participation in clinical trials and physician training programs."

Since its inception, the company has strived to offer efficient diagnostic solutions in areas such as colon cancer screening, cardiac analysis and vascular analysis. Through its innovative, cost- effective offerings that reduce read time, Viatronix applications optimize the utilization of CT scanners.

"Grasping the potential offered by the fast growing PACS market, the Company has added a robust PACS interface to its clinical applications, besides offering software-only solutions," says Kumar. "Viatronix has, therefore, not only tapped into the trend of offering advanced visualization technologies through PACS, but has also successfully kept itself at the forefront of developing market trends for end users to turn to high-end, organ-specific clinical solutions as opposed to general purpose 3D imaging."

In 2005, Viatronix entered into a partnership with Eastman Kodak Company (now known as Carestream), a global leader in advanced healthcare products. The company successfully integrated its V3D-Colon application into the CARESTREAM PACS System, allowing Viatronix to leverage the sales and marketing potential of Carestream to reach an extensive customer base.

Viatronix also entered into separate agreements with iCAD Inc., and Medicsight PLC regarding the integration of colon CAD. The Company has also signed an agreement with Visage Imaging Inc., for the distribution of it V3D-Colon platform.

"As the medical imaging world moves from a 2D arena to 3D arena, Viatronix's primary marketing efforts have been to sponsor and offer educational programs to radiologists," remarks Kumar. "Along with additional on-site training rendered to physicians, these educational programmes have made the technological barrier as simple as possible for physicians."

In Dec. 2003 in the landmark clinical trial published in the New England Journal of Medicine that put virtual colonoscopy on the world map and for the first time showed a high degree of sensitivity and specificity, the Viatronix V3D-Colon platform was the only platform used. Subsequent to the 2003 clinical trial, the Viatronix V3D-Colon product has been used in many clinical trials in Europe and the U.S. Viatronix V3D-Colon remains the only module on the market with a large number of clinical trials under its belt with more on their way.

The base 3D visualization workflow that has been developed by Viatronix is now being utilized into developing different organ-specific clinical applications in a cost-effective manner. The company is currently focused on the roll out of its V3D-Cardiac module which is expected to be another industry leading product.

"Viatronix enjoys a competitive edge by having similar workflows and a simple look and feel across all of its products," concludes Kumar. "Also, by providing software-only, organ-specific modules, Viatronix has gained an aggressive advantage over competitors who either require specific hardware for their applications and/or require the end user to purchase a base module before being able to acquire organ specific clinical applications."

The Frost & Sullivan Award for Emerging Company of the Year is presented to the company that has emerged as a significant participant within its industry. This company is perceived to have exhibited outstanding management, superior market growth, exceptional customer service and the ability to combine technology and successful strategic initiatives. This company has the exceptional know-how to take advantage of market changes through the execution of innovative strategies within the existing competitive landscape.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Viatronix

Viatronix is a leading innovator and developer of 2D/3D medical imaging and diagnostic software. The software enables physicians to interactively view vital organs and anatomical structures within the human body from data acquired by standard medical imaging equipment in minimally or non-invasive methods. Viatronix, through application of the V3D(R) technology, is developing additional innovative products that will be useful in early detection of other diseases, treatment planning, intervention, and follow-up evaluation.

Viatronix, Inc. is located in Stony Brook, NY. To learn more, call us toll free at 1-866-887-4636 or log on to www.viatronix.com.

    Contact: Susan Barclay, Marketing, Viatronix, Inc.
    slevin@viatronix.com
    P: + 011.631.444-6181

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 35 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

    Contact: Catherine Brassell, Best Practices, Frost & Sullivan
    catherine.brassell@frost.com
    P: +44.207.915.7867

SOURCE Frost & Sullivan


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Mennen Medical Receives Frost & Sullivan 2009 European Patient Monitoring Technology Leadership Award
2. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
3. Robbins & Myers Announces Regular Quarterly Cash Dividend
4. Sigma-Aldrich (Nasdaq: SIAL) Announces Appointment of George Miller as Sr. Vice President, General Counsel & Secretary
5. Tata Interactive Systems Partners With Bersin & Associates for Exclusive Executive Learning Forum - TLF 2009
6. Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes
7. ARUP Laboratories Applauds FDAs Decision on the Value of KRAS-Mutation Testing in Colorectal Cancer
8. Society of Interventional Radiology Applauds Reports Uterine Fibroid Embolization Recommendations
9. Wyeth Applauds Six Countries Across Europe, and the Middle East, That Recently Announced the Inclusion of the 7-Valent Pneumococcal Conjugate Vaccine (PCV7) in Their Immunization Schedules
10. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
11. Viatronix V3D-Colon Utilized in Another Landmark Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... PARIS , May 25,2016 ... with the near-infrared Cellvizio platform for urological and ... MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary ... important regulatory milestone in the US with the ... Food and Drug Administration (FDA). This new FDA ...
(Date:5/25/2016)... and GERMANTOWN, Maryland , May 25, 2016 ... ; Frankfurt Prime Standard: QIA) today announced that the company ... Diagnostics GmbH to develop and commercialize predictive assays in oncology. ... as a marker to predict effectiveness of anthracycline treatment in ... "We are pleased to partner with Therawis, which developed the ...
(Date:5/25/2016)... NEW YORK , May 25, 2016 ... Device Market Size, Share, Development, Growth and Demand Forecast ... Insulin Syringe, Insulin Pump and Others)" published by P&S ... valued at $9,998.3 million in 2015, and it is ... 2016-2022. Based on type, the insulin pump segment is ...
Breaking Medicine Technology:
(Date:5/30/2016)... GA (PRWEB) , ... May 30, 2016 , ... ... on June 6th, while Shaolin warrior 8-day-8 and 8-night special intensive summer training ... Shaolin Institute annual overnight summer camp offers families and children a fun and ...
(Date:5/29/2016)... , ... May 29, 2016 , ... Whole Health Supply ... their new KlipPro KP-240L clipper is available to the public. This is an unusual ... substantially wider than the average clipper. , Everything about this product is concentrated on ...
(Date:5/28/2016)... ... May 28, 2016 , ... "Color Grading media can be time consuming ... onto their media," said Christina Austin - CEO of Pixel Film Studios. , ... easily add stylish color grades to their footage. A LUT is a Lookup Table ...
(Date:5/28/2016)... ... 2016 , ... In a part of the city where’s it’s easy to spot the neon ... is hoping to attract diners with a taste for real food. , On ... doors to Cornerstone Grill, an urban casual restaurant focusing on dishes made by hand with ...
(Date:5/27/2016)... ... ... Two director-level employees of Horizon Blue Cross Blue Shield of New Jersey ... The award recognizes businesswomen who excel in their fields and who have made ... (Managed Long-Term Services and Supports) Program at Horizon NJ Health and Theresa Ponton, Director ...
Breaking Medicine News(10 mins):